Background Statin is known to be effective in reducing major adverse cardiovascular events (MACE) in patients (pts) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). This study is to investigate the efficacy of so called ���potent statins��� (rosuvastatin, atovastatin and pitavastatin) with other ���moderate statins��� (including simvastatin, pravastatin and fluvastatin) in a series of Asian population. Methods The study population consisted of 1,175 consecutive patients (pts) undergoing PCI with DESs from November 2005 to June 2008. Angiographic outcomes at 6 months and cumulative clinical outcomes up to 2 years were compared between the potent statin group (n= 998 pts, 84.9%) and moderate statin group (n=177 pts, 15.1%). Results Both groups had similar baseline clinical and procedural characteristics except the Potent statin group had higher baseline level of total cholesterol and low density lipoprotein (LDL)-cholesterol, higher left ventricular ejection fraction (LVEF) and higher incidence of ST elevation myocardial infarction (STEMI). Six-month angiographic outcomes and major clinical outcomes including cardiac death, Q wave MI, TVR and TVR MACEs were similar between the two groups up to 2 years (Table). Conclusions Administration of statins, whether potent statin or moderate statin, showed similar clinical outcomes up to two years with similar safety and efficacy in pts undergoing PCI with DES in a series of Asian population.